---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-25-000003"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2025-01-22T23:59:59+00:00"
generated_at: "2026-05-27T21:18:06.154221+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# JNJ Q4 net earnings down 17%, revenue up 5.3% to $22.52B; adjusted EPS $2.04

## Summary
- Q4 sales $22.52B, +5.3% YoY; net earnings $3.43B, -17% from $4.13B; diluted EPS $1.41.
- Adjusted net earnings $4.95B, adjusted EPS $2.04, down 10.9% from $2.29.
- Innovative Medicine (ex-COVID) sales $14.33B (+4.8%); MedTech sales $8.19B (+6.7%).
- R&D expense rose 18.3% to $5.30B; operating margin contracted to 17.3% from 22.6%.
- Full-year sales $88.82B, +4.3% vs $85.16B; ex-COVID sales +5.5%.

## SEC filing metadata
- accession: 0000200406-25-000003
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2025-01-22T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040625000003/0000200406-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040625000003/jnj-20250122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-25-000003
- JSON: https://secwatch.observer/filing/0000200406-25-000003.json
- Plain text: https://secwatch.observer/filing/0000200406-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.